Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor

NCT03406364 | Completed Phase 1 FDA Drug

• 1 other identifier: MEOMG1A20170313
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

The proposed initial trial is a Phase I, open label study to evaluate the safety and explore efficacy of MG005 in combination with sorafenib in patients with solid tumor. The eligible patients will receive 200 mg of sorafenib with 3 pre-defined dose levels of GW5074, escalated from 750 mg to 1500 mg (daily dose), to determine the Maximum Tolerated Dose (MTD) and dose limiting toxicities (DLT) (if any) at Phase I stage.

Conditions

Solid Tumor

Outcome Measures

Primary Outcomes (2)

• Maximum Tolerated Dose(MTD)and Dose Limiting(DLT) -phase I

  MTD by defining DLTs for MG005 and in combination with sorafenib.

  DLTs will be assessed during the initial 8-week treatment periods for Cohort 1.

• Maximum Tolerated Dose(MTD)and Dose Limiting(DLT) -phase I

  MTD by defining DLTs for MG005 and in combination with sorafenib.

  DLTs will be assessed during the initial 4-week treatment periods for Cohort 2/3

Study Arms (1)

MG005

EXPERIMENTAL

Cohort 1 :3 × 250 mgMG005+1 × 200 mgSorafenib\[8:00 AM (±2 hours)\] Cohort 2 :6 × 250 mgMG005+1 × 200 mgSorafenib\[8:00 AM (±2 hours)\] Cohort 3 :3 × 250 mgMG005+1 × 200 mgSorafenib; 3 × 250 mgMG005+1 × 200 mgSorafenib\[8:00 AM (±2 hours); 8:00 PM (±2 hours)\]

Drug: MG005

Interventions

MG005 DRUG

Phase I: Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy.

MG005

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient who is able to understand the nature of this study and accepts to enter the study by signing written informed consent
• Patients who are ≥ 20 years of age
• Patients with histologically confirmed advanced or metastatic disease that is either refractory to or intolerant of existing standard therapy or for which no effective standard therapy that confers clinical benefit is available (patients may have received prior therapy with sorafenib if not intolerable)
• Patient has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
• Patient able to provide either an archived tumor sample or with accessible tumor for biopsy and willingness to provide it prior to initiation of study treatment
• At least 4 weeks post any therapeutic modalities (e.g., surgery, radiotherapy, and therapeutic agents) prior to initial dosing except the palliative radiotherapy performed on non-study-related local lesions
• Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2 8.Patient's life expectancy of at least 3 months
• Patient has adequate hematopoietic, hepatic function and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
• Hemoglobin ≥ 9.0 g/dL
• Absolute neutrophil count (ANC) ≥ 1,500 cells/μL
• Total white blood cell (WBC) ≥ 3,000 cells/μL
• Platelet ≥ 100,000 counts/μL
• Total bilirubin ≤ 1.5× upper limit of normal (ULN) and no sign of jaundice
• ALT and AST ≤ 2.5× ULN (≤ 5× ULN for patients with liver involvement)
• ALP ≤ 5× ULN

You may not qualify if:

• Patient who has participated in other investigational studies and received any investigational therapy within 4 weeks prior to study dosing
• Patient carries history of primary malignancy other than the entry diagnosis except curatively treated non-melanoma skin cancer, cervical carcinoma in situ, or superficial bladder tumors within 5 years prior to study entry.
• Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of GW5074 and sorafenib (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
• Patient with known leptomeningeal or brain metastasis (including those who require glucocorticoids or intrathecal chemotherapy) by radiologic/histological evidence, or only bone metastasis
• Patient with history of significant cardiac disease including superior vena cava, unstable angina, congestive heart failure \> class 2 per New York Heart Association (NYHA) classification, cardiac arrhythmias, cardiac ischemia/infarction, long QT-syndrome (i.e., QTc \> 450 msec for males and \> 470 msec for females), poorly controlled hypertension (systolic blood pressure \> 150 mm-Hg and/or diastolic blood pressure \> 90 mm-Hg on anti-hypersensitive medications), and valvular heart disease
• History of organ or bone marrow transplant
• Patient who has not recovered from side/toxic effects of previous therapy (i.e., NCI-CTCAE grade 1 or less) prior to the first dose of study medications
• Patients who are receiving or with conditions requiring substances that are potent inducers of CYP3A4 activity (e.g., rifampin, St. John's wort, phenytoin, carbamazepine, phenobarbital, and dexamethasone)
• Patients who are receiving or with conditions requiring sensitive substrates of CYP1A2, 1B1, 2C8, 2C19 and 3A4 with narrow therapeutic windows (e.g., theophylline, duloxetine, alosetron, tizanidine, repaglinide, omeprazole, S-mephenytoin, alfentanil, sirolimus, pimozide, and tacrolimus)
• History of stroke or transient ischemic attack within 6 months of study entry
• Patient with any hemorrhage/bleeding event (e.g., non-healing wound, ulcer, and bone fracture) ≥ NCI-CTCAE grade 2 within 28 days prior to study treatment, or history of bleeding diathesis or coagulopathy
• Patients with poorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months
• Patients with HIV, acute HBV, and HCV (except hepatitis carriers) infections
• Patient with known or suspected hypersensitivity to any agent given in the course of this trial
• Patient with underlying medical, mental or psychological conditions that would impair the treatment compliance, or in the opinion of the investigator would not permit to participate in the study

Sponsors & Collaborators

• Metagone Biotech Inc.: lead

Study Sites (1)

Tri-Service General Hospital

Taipei, Nehu District, 114, Taiwan

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Phase I: Eligible subjects will receive 1 of 3 different dosages of the combination therapy of GW5074 and sorafenib. The dose cohorts include: * Monotherapy with 750 mg QD GW5074, followed by 750 mg QD GW5074 + 200 mg QD Sorafenib * 1500 mg QD GW5074 + 200 mg QD Sorafenib * 750 mg BID GW5074 + 200 mg QD Sorafenib

Study Record Dates

• First Submitted: January 8, 2018
• First Posted: January 23, 2018
• Study Start: June 6, 2018
• Primary Completion: January 9, 2020
• Study Completion: July 24, 2020
• Last Updated: April 26, 2021

Record last verified: 2021-04

Locations

TW (1)